Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, United States.
Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, United States.
Elife. 2023 Jan 24;12:e84302. doi: 10.7554/eLife.84302.
The lissencephaly 1 protein, LIS1, is mutated in type-1 lissencephaly and is a key regulator of cytoplasmic dynein-1. At a molecular level, current models propose that LIS1 activates dynein by relieving its autoinhibited form. Previously we reported a 3.1 Å structure of yeast dynein bound to Pac1, the yeast homologue of LIS1, which revealed the details of their interactions (Gillies et al., 2022). Based on this structure, we made mutations that disrupted these interactions and showed that they were required for dynein's function in vivo in yeast. We also used our yeast dynein-Pac1 structure to design mutations in human dynein to probe the role of LIS1 in promoting the assembly of active dynein complexes. These mutations had relatively mild effects on dynein activation, suggesting that there may be differences in how dynein and Pac1/LIS1 interact between yeast and humans. Here, we report cryo-EM structures of human dynein-LIS1 complexes. Our new structures reveal the differences between the yeast and human systems, provide a blueprint to disrupt the human dynein-LIS1 interactions more accurately, and map type-1 lissencephaly disease mutations, as well as mutations in dynein linked to malformations of cortical development/intellectual disability, in the context of the dynein-LIS1 complex.
无脑回畸形蛋白 1(LIS1)在 1 型无脑回畸形中发生突变,是细胞质动力蛋白-1 的关键调节因子。在分子水平上,目前的模型提出 LIS1 通过解除其自动抑制形式来激活动力蛋白。此前我们报道了酵母动力蛋白与 Pac1(LIS1 的酵母同源物)结合的 3.1Å 结构,该结构揭示了它们相互作用的细节(Gillies 等人,2022 年)。基于该结构,我们进行了突变,破坏了这些相互作用,并表明它们是酵母体内动力蛋白功能所必需的。我们还使用酵母动力蛋白-Pac1 结构来设计人源动力蛋白中的突变,以探究 LIS1 在促进活性动力蛋白复合物组装中的作用。这些突变对动力蛋白的激活有相对温和的影响,这表明在酵母和人类之间,动力蛋白和 Pac1/LIS1 的相互作用可能存在差异。在这里,我们报告了人源动力蛋白-LIS1 复合物的冷冻电镜结构。我们的新结构揭示了酵母和人类系统之间的差异,提供了更精确地破坏人源动力蛋白-LIS1 相互作用的蓝图,并在动力蛋白-LIS1 复合物的背景下映射了 1 型无脑回畸形疾病突变以及与皮质发育/智力障碍相关的动力蛋白突变。